NCT05910437

Optimizing Treatments for Heart Failure During Hospitalization

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 184 (actual)
• Sponsor: Central Hospital, Nancy, France · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year. Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2). Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality. The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.

Conditions

• Decompensated Heart Failure

Interventions

Type	Name	Description
OTHER	Hospitalized patient for decompensated heart failure	Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.

Timeline

• Start date: 2023-08-08
• Primary completion: 2023-11-29
• Completion: 2023-11-29
• First posted: 2023-06-18
• Last updated: 2026-02-13

Locations

2 sites across 1 country: France